|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0008976,
umls-concept:C0014582,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0038952,
umls-concept:C0085533,
umls-concept:C0442805,
umls-concept:C0443252,
umls-concept:C0746319,
umls-concept:C1257890,
umls-concept:C1274040,
umls-concept:C1510810,
umls-concept:C1522577,
umls-concept:C1556084
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2005-4-19
|
|
pubmed:abstractText |
The French Adjuvant Study Group 05 (FASG-05) showed that fluorouracil 500 mg/m2, cyclophosphamide 500 mg/m2, and epirubicin 100 mg/m2 (FEC 100) was superior to the same regimen with epirubicin 50 mg/m2 (FEC 50) in terms of disease-free survival (DFS) and overall survival (OS) in adjuvant treatment of early breast cancer. We report 10-year data on efficacy, and long-term side effects for FASG-05.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
20
|
|
pubmed:volume |
23
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2686-93
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15837983-Adult,
pubmed-meshheading:15837983-Aged,
pubmed-meshheading:15837983-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:15837983-Breast Neoplasms,
pubmed-meshheading:15837983-Chemotherapy, Adjuvant,
pubmed-meshheading:15837983-Cyclophosphamide,
pubmed-meshheading:15837983-Disease-Free Survival,
pubmed-meshheading:15837983-Dose-Response Relationship, Drug,
pubmed-meshheading:15837983-Epirubicin,
pubmed-meshheading:15837983-Female,
pubmed-meshheading:15837983-Fluorouracil,
pubmed-meshheading:15837983-Follow-Up Studies,
pubmed-meshheading:15837983-Heart,
pubmed-meshheading:15837983-Humans,
pubmed-meshheading:15837983-Infusions, Intravenous,
pubmed-meshheading:15837983-Middle Aged,
pubmed-meshheading:15837983-Neoplasms, Second Primary,
pubmed-meshheading:15837983-Prognosis
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial.
|
|
pubmed:affiliation |
Département d'Oncologie Médicale, Centre Oscar Lambret, 3 rue Frédéric Combemale, 59020 Lille Cedex, France. j-bonneterre@o-lambret.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
